<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975895</url>
  </required_header>
  <id_info>
    <org_study_id>031-16</org_study_id>
    <nct_id>NCT02975895</nct_id>
  </id_info>
  <brief_title>Outcome of Different IOLs in Patients With and Without Uveitis</brief_title>
  <official_title>Outcome With Hydrophobic and Hydrophilic Intraocular Lens in Patients With and Without Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cataract, is a clouding of the lens in the eye gradually leading to reduction of the visual
      acuity. In most cases it can be managed with surgery, removing the own lens and replacing it
      with an artificial lens, intraocular lens (IOL). These lenses are made in different materials
      with different properties.

      Uveitis refers to an inflammation in the iris, ciliary body and choroid. Patients with this
      disease have an increased risk of developing cataract due to the inflammation itself and
      treatment with steroids. They also have an increased risk of complications during surgery and
      postoperatively. In this group the selection of IOL might be of greater importance.

      The aim of this prospective randomized controlled study is to compare the outcome of
      hydrophobic and hydrophilic intraocular lenses in patients with and without uveitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory response</measure>
    <time_frame>Preoperatively and at seven occasions within two years postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of posterior capsule opacification after six months</measure>
    <time_frame>Six months (plus or minus 30 days) postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of posterior capsule opacification after one year</measure>
    <time_frame>One year (plus or minus 30 days) postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of posterior capsule opacification after two years</measure>
    <time_frame>Two years (plus or minus 2 months) postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity assessed in decimal using Snellen charts</measure>
    <time_frame>Preoperatively and at six occasions within two years postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Preoperatively and at seven occasions within two years postoperatively</time_frame>
    <description>Postoperative glaucoma or cystoid macular edema</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Uveitis</condition>
  <condition>Cataract</condition>
  <condition>Inflammation</condition>
  <condition>Posterior Capsule Opacification</condition>
  <arm_group>
    <arm_group_label>Hydrophobic IOL: Vivinex (HOYA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intraocular lens with hydrophobic properties: Vivinex (HOYA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrophilic IOL: INCISE (Bausch+Lomb)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrophobic IOL: Vivinex (HOYA)</intervention_name>
    <description>Patients requiring cataract surgery will be randomized to one of the two types of IOLs.</description>
    <arm_group_label>Hydrophobic IOL: Vivinex (HOYA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrophilic IOL: INCISE (Bausch+Lomb)</intervention_name>
    <description>Patients requiring cataract surgery will be randomized to one of the two types of IOLs.</description>
    <arm_group_label>Hydrophilic IOL: INCISE (Bausch+Lomb)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cataract requiring surgery

          -  Ability to understand and sign consent form

        Exclusion Criteria:

          -  Extensive corneal scarring

          -  Other eye surgery less than 3 months before inclusion

          -  Unregulated glaucoma

          -  Active uveitis (increased inflammation and treatment less than 3 months before
             inclusion)

          -  Intraoperative complications (capsular tear or vitreous loss)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madeleine Zetterberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Västra Götalands regionen, Sahlgrenska University Hospital, Department of Ophthalmology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Pålsson, MD</last_name>
    <phone>0046-735832061</phone>
    <email>sara.palsson@vgreion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology</name>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madeleine Zetterberg, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

